Zacks Investment Research downgraded shares of Portola Pharmaceuticals (NASDAQ:PTLA) from a hold rating to a sell rating in a report published on Tuesday morning.
According to Zacks, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. “
Several other research analysts have also recently commented on the company. Oppenheimer set a $80.00 price target on Portola Pharmaceuticals and gave the stock a buy rating in a research note on Monday, January 15th. Goldman Sachs Group initiated coverage on Portola Pharmaceuticals in a research note on Friday, December 1st. They issued a buy rating and a $75.00 price target on the stock. BidaskClub cut Portola Pharmaceuticals from a sell rating to a strong sell rating in a research note on Thursday, December 7th. Citigroup reiterated a buy rating and issued a $74.00 price target on shares of Portola Pharmaceuticals in a research note on Thursday, December 28th. Finally, William Blair reiterated a buy rating on shares of Portola Pharmaceuticals in a research note on Monday, January 1st. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $70.65.
Portola Pharmaceuticals (NASDAQ PTLA) opened at $45.10 on Tuesday. The company has a quick ratio of 8.31, a current ratio of 8.31 and a debt-to-equity ratio of 0.24. Portola Pharmaceuticals has a one year low of $29.50 and a one year high of $67.10. The company has a market capitalization of $2,940.00, a PE ratio of -10.44 and a beta of 1.18.
In other Portola Pharmaceuticals news, Director Henry Ward Wolff sold 12,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $47.00, for a total transaction of $564,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 5.50% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. QS Investors LLC acquired a new stake in Portola Pharmaceuticals during the second quarter valued at approximately $147,000. Oppenheimer Asset Management Inc. raised its stake in Portola Pharmaceuticals by 251.2% during the third quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 2,047 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Portola Pharmaceuticals by 54.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,219 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 1,141 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in Portola Pharmaceuticals during the third quarter valued at approximately $178,000. Finally, Sei Investments Co. acquired a new stake in Portola Pharmaceuticals during the third quarter valued at approximately $217,000. Hedge funds and other institutional investors own 87.78% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Portola Pharmaceuticals (PTLA) Lowered to “Sell” at Zacks Investment Research” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/14/portola-pharmaceuticals-ptla-lowered-to-sell-at-zacks-investment-research.html.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.